Prostate Cancer Clinical Trial
Official title:
Xbox Kinect Training in Men With Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy
| Verified date | February 2019 |
| Source | Hospitalsenheden Vest |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to investigate the effect of 12 weeks systematically training
using the Xbox Kinect system.
Outcome measures are made on physical function, quality of life, fatigue and metabolic
parameters.
| Status | Completed |
| Enrollment | 46 |
| Est. completion date | June 2018 |
| Est. primary completion date | June 2018 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 40 Years and older |
| Eligibility |
Inclusion Criteria: - Prostate cancer requiring androgen deprivation therapy - Androgen deprivation therapy for at least 3 month prior to inclusion - Cognitive well-functioning in order to be able to answer questionnaires and train according to instructions - Signed informed consent Exclusion Criteria: - Prostate cancer with metastasis to other regions than bones - Strength- or cardiovascular training 2 times or more per week prior to inclusion - Haemoglobin percentage less than 6,1 mmol/l - Any mental or physical condition that makes the patient unfit for participation - Men in risk of getting an osteoporotic fracture due to long-term treatment with steroids or earlier fractures due to minimal trauma - Participation in other studies |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Urinvejskirurgisk afdeling, Aarhus Universitetshospital, Skejby | Aarhus | |
| Denmark | Regionshospitalet Holstebro, Urinvejskirurgisk afdeling | Holstebro | |
| Denmark | Urologisk afdeling, Regionshospitalet Viborg | Viborg |
| Lead Sponsor | Collaborator |
|---|---|
| Hospitalsenheden Vest |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The effect of 12 weeks systematically training with the Xbox Kinect system on physical function | 6 min walk test | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect on body composition | Method: BIoelectrical impedance analysis Bioelectrical impedance | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on physical function | Leg extensor power | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on fatigue | Fatigue measured using the Functional Assessment of Canter Therapy-Fatigue questionnaire | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on quality of life | Quality of life measured using the Functional Assessment of Canter Therapy-Prostate questionnaire | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Waist circumference (cm) | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Blood pressure (mmHg) | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Body weight (kg) | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Blood glucose (mmol/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Plasma triglyceride (mmol/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Plasma cholesterol (mmol/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Plasma High-density lipoprotein (HDL-cholesterol) (mmol/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Plasma Low-density lipoprotein (LDL-cholesterol) (mmol/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Leptin (µg/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Adiponectin (mg/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on metabolic parameters | Leptin:Adiponectin ratio | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on the prevalence of the metabolic syndrome | The five components of the metabolic syndrome: blood glucose, triglyceride, HDL-cholesterol, waist circumference, blood pressure | Change from baseline to week 12 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on insulin | Insulin (pmol/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on insulin resistance | Homeostasis model assessment for insulin resistance (HOMA-IR) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on Insulin Growth Factor-I (IGF-I), bioactive IGF, and IGF-II | IGF-I, bioactive IGF and IGF-II (µg/L) | Change from baseline to week 12 and week 24 | |
| Secondary | The effect of 12 weeks systematically training with the Xbox Kinect system on Insulin Growth Factor Binding Protein 1-3 (IGFBP 1-3) | IGFBP 1-3 (µg/L) | Change from baseline to week 12 and week 24 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
| Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
| Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |